Donafenib vs Sorafenib in First-Line Treatment of Unresectable or Metastatic HCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
J. Clin. Oncol 2021 Sep 20;39(27)3002-3011, S Qin, F Bi, S Gu, Y Bai, Z Chen, Z Wang, J Ying, Y Lu, Z Meng, H Pan, P Yang, H Zhang, X Chen, A Xu, C Cui, B Zhu, J Wu, X Xin, J Wang, J Shan, J Chen, Z Zheng, L Xu, X Wen, Z You, Z Ren, X Liu, M Qiu, L Wu, F ChenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.